Molnupiravir (EIDD-2801; MK4482; prodrug-EIDD1931; MK-4482; trade name Lagevrio) is a novel, potent and orally bioavailable prodrug of the ribonucleoside analog EIDD-1931 with a broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as COVID-19, SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for treating COVID-19, and seasonal and pandemic influenza treatment. On Nov 4th 2021, Molnupiravir was approved in Britain to the fight against the COVID-19 pandemic. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus.

纯度：≥98%

CAS：2349386-89-4